Evidence map›Paper›PMID 25330819›Full record

ArticleAnnals of gastroenterology2014

First- and second-line

Angelo Zullo, Lorenzo Ridola, Cesare Efrati, Floriana Giorgio, Giorgia Nicolini, Claudio Cannaviello, Domenico Alvaro, Cesare Hassan, Luigi Gatta, Vincenzo De Francesco

Abstract read
PubMed Full text at PMC
In one paragraph

Article in Annals of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Rescue Therapies forAntibiotics (Basel, Switzerland) · 2021
    Article
  2. Vaccine against Helicobacter pylori: Inevitable approach.World journal of gastroenterology · 2016
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Angelo ZulloGastroenterology and Digestive Endoscopy, "Nuovo Regina Margherita" Hospital Rome (Angelo Zullo, Cesare Hassan), Italy.
Lorenzo RidolaGastroenterology Unit, Sapienza University of Rome, "Polo Pontino" Hospital, Latina (Lorenzo Ridola, Domenico Alvaro), Italy.
Cesare EfratiGastroenterology and Digestive Endoscopy, Israelitic Hospital, Rome (Cesare Efrati, Giorgia Nikolini, Claudio Cannaviello), Italy.
Floriana GiorgioEndoscopy Unit, Ruiniti Hospital, Foggia (Floriana Giorgio, Vincenzo De Francesco), Italy.
Giorgia NicoliniGastroenterology and Digestive Endoscopy, Israelitic Hospital, Rome (Cesare Efrati, Giorgia Nikolini, Claudio Cannaviello), Italy.
Claudio CannavielloGastroenterology and Digestive Endoscopy, Israelitic Hospital, Rome (Cesare Efrati, Giorgia Nikolini, Claudio Cannaviello), Italy.
Domenico AlvaroGastroenterology Unit, Sapienza University of Rome, "Polo Pontino" Hospital, Latina (Lorenzo Ridola, Domenico Alvaro), Italy.
Cesare HassanGastroenterology and Digestive Endoscopy, "Nuovo Regina Margherita" Hospital Rome (Angelo Zullo, Cesare Hassan), Italy.
Luigi GattaGastroenterology and Digestive Endoscopy; "Versilia" Hospital, Lido di Camaiore (Luigi Gatta), Italy.
Vincenzo De FrancescoEndoscopy Unit, Ruiniti Hospital, Foggia (Floriana Giorgio, Vincenzo De Francesco), Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHelicobacter pylori (

methodsIn this prospective, open label, multicenter, pilot study

resultsA total of 99 and 15 patients were enrolled for first- and second-line therapy. The eradication rates were 85.9% (95% CI 80-93) and 93.4% (95% CI 88-98) according to ITT and PP analyses following modified sequential therapy, and 60% (95% CI 35-86) and 64.3% (95% CI 39-89) following the intensified second-line therapy.

conclusionA modified sequential 3- plus 7-day regimen with thrice daily drug administration failed to achieve very high eradication rate at ITT analysis. The intensified second-line regimen achieved disappointingly low eradication rate. Novel levofloxacin-free second-line therapies are urged in Italy.

Indexed as

Helicobacter pylorimodified levofloxacin triple therapymodified sequential therapysecond-line therapysequential therapytherapy

Identifiers

PMID25330819
PMCPMC4188933

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.